Foghorn Therapeutics (FHTX) Operating Income (2020 - 2025)
Historic Operating Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$18.5 million.
- Foghorn Therapeutics' Operating Income rose 2243.42% to -$18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.5 million, marking a year-over-year increase of 1692.02%. This contributed to the annual value of -$102.7 million for FY2024, which is 484.03% up from last year.
- Per Foghorn Therapeutics' latest filing, its Operating Income stood at -$18.5 million for Q3 2025, which was up 2243.42% from -$21.1 million recorded in Q2 2025.
- Over the past 5 years, Foghorn Therapeutics' Operating Income peaked at -$17.1 million during Q3 2023, and registered a low of -$33.3 million during Q1 2023.
- In the last 5 years, Foghorn Therapeutics' Operating Income had a median value of -$26.3 million in 2021 and averaged -$25.8 million.
- As far as peak fluctuations go, Foghorn Therapeutics' Operating Income plummeted by 6853.69% in 2021, and later surged by 3955.55% in 2023.
- Foghorn Therapeutics' Operating Income (Quarter) stood at -$28.1 million in 2021, then dropped by 13.55% to -$31.9 million in 2022, then grew by 20.16% to -$25.5 million in 2023, then increased by 5.71% to -$24.0 million in 2024, then rose by 22.93% to -$18.5 million in 2025.
- Its Operating Income was -$18.5 million in Q3 2025, compared to -$21.1 million in Q2 2025 and -$22.9 million in Q1 2025.